新疗法竞争引入后药品净价格和药品支出的变化,2011-19年
Sean Dickson1, Nico Gabriel2, Inmaculada Hernandez3
1Sean Dickson, West Health Policy Center, Washington, D.C.
Health affairs (Project Hope)
|August 7, 2023
概括
新药竞争显著降低了药品净价格,减少了104亿美元的支出. 这与上的目录价格形成鲜明对比,显示出竞争.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 药品定价分析 药品定价分析
背景情况:
- 现有研究表明,新的制药竞争对手不会降低清单价格.
- 新疗法竞争对药品净价格的影响仍未得到充分研究.
研究的目的:
- 系统地评估新的治疗竞争如何影响药品净价格.
- 量化新兴药品对药品总体支出的影响.
主要方法:
- 确定2013-2017年间批准的新疗法作为现有治疗方法的竞争对手.
- 利用一种新的算法来估计现有疗法的净价格.
- 采用回归模型来分析竞争引入后 (2011-2019) 的净价格变化.
主要成果:
- 新的治疗竞争与12个治疗类的年度净价格增长下降4.2%相关.
- 引入新的品牌疗法减少了10.4亿美元 (18.5%的减少) 的现有药物的净支出.
结论:
- 新的治疗竞争使药房福利管理人员能够通过配方管理来降低药品净价格.
- 竞争有效地减少了药品总体支出,与目录价格通胀的趋势有所不同.
相关概念视频
Prescription, Nonprescription and Orphan Drugs
765
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
765
Combined Effects of Drugs: Antagonism
8.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.6K
Drug Nomenclature
1.8K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.8K
Bioequivalence: Overview
1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Issues And Trends In Healthcare Delivery System
5.7K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.7K
Drug Control Governance: Regulatory Bodies and Their Impact
184
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
184


